Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Description

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.

Conditions

Alzheimer Dementia, Agitation,Psychomotor

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.

Effect and Safety of Electroconvulsive Therapy Plus Usual Care for the Acute Management of Severe Agitation in Dementia

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Condition
Alzheimer Dementia
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory Healthcare, Atlanta, Georgia, United States, 30308

Belmont

McLean Hospital, Belmont, Massachusetts, United States, 02478

Grand Rapids

Pine Rest Christian Mental Health Services, Grand Rapids, Michigan, United States, 49548

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Glen Oaks

Northwell Health, Glen Oaks, New York, United States, 11004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Current diagnosis of co-morbid delirium, measured by the Confusion Assessment Measure (CAM) and by clinical diagnosis
  • 2. Diagnosis of vascular dementia due to stroke, based on:
  • * History consistent with abrupt onset and step-wise progression of cognitive and functional decline
  • * MRI scan within the past 12 months demonstrating evidence of hemorrhagic and embolic stroke
  • * Physical and neurologic examination consistent with current or prior stroke
  • 3. Lifetime or current diagnosis of Schizophrenia, Bipolar Disorder or Schizoaffective Disorder
  • 4. Active substance use disorder within past 6 months
  • 5. Treatment with ECT or other neurostimulation therapies (e.g., TMS or vagal nerve stimulation) within the past 3 months

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brent Forester,

Brent P Forester, MD, MSc, PRINCIPAL_INVESTIGATOR, Mclean Hospital

George Petrides, MD, PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

2025-05-31